Oncology Xagena
A study of Bevacizumab ( Avastin ) plus Paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of improving progression-free survival, compared to chemothera ...
A joint interim analysis of two studies of Trastuzumab ( Herceptin ) in early-stage breast cancer showed that HER2-positive breast cancer patients receiving Herceptin plus chemotherapy had a 52 perce ...
Gamma-linolenic acid ( GLA ), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 pe ...
A large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin ( Trastuzumab ) to chemotherapy significantly reduces the risk of disease recurrence compared to che ...
A research into the cost of using the breast cancer drug Herceptin ( Trastuzumab ) warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breas ...
Herceptin ( Trastuzumab ), a recombinant monoclonal antibody against HER2, previously shown to prolong survival in advanced breast cancer, reduced the recurrences in patients with early-stage disease ...
Researchers have presented the combined results of two trials that compared adjuvant chemotherapy with or without concurrent Herceptin ( Trastuzumab ) in women with surgically removed HER2-positive br ...
The therapy Herceptin with chemotherapy in patients with early stage breast cancer significantly increases disease-free survival time in women who test positive for a genetic mutation. The study al ...
A study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system. This study is the first to indicate that the drug Tra ...
A study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may cause breast can ...
A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...
Data from TAnDEM study have shown that the addition of Trastuzumab ( Herceptin ) to the hormonal therapy, Anastrozole ( Arimidex ), improves progression-free survival for patients whose advanced breas ...
Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective ...
A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks wit ...
Researchers in the North Central Cancer Treatment Group ( NCCTG ) have shown that patients who receive Trastuzumab ( Herceptin ) at the same time as post-chemotherapy radiation treatments for HER-2 po ...
